Multidisciplinary approach to connective tissue disease (CTD) related pleural effusions: a four-year retrospective evaluation

Hugh Ip*, Parthipan Sivakumar, Eugene Ace McDermott, Sangita Agarwal, Boris Lams, Alex West and Liju Ahmed

Abstract

Background: CTD-related pleural effusions are rare and challenging to diagnose. Our lung inflammation service (with expertise in rheumatology, interstitial lung disease and respiratory failure) works closely with the pleural team. This study aims to review the multidisciplinary approach to CTD-related pleural effusions at a tertiary centre.

Methods: All patients with CTD-related pleural effusions at St Thomas' Hospital, London were included. Retrospective data were collected from Dec 2013 to 2016.

Results: The lung inflammation service performed an expert clinical assessment and targeted investigations. 11 patients (ages 23–77) were identified with CTD related pleural disease. 9 (82%) patients were given a new CTD diagnosis, with pleural disease as the first manifestation. The range of conditions were: rheumatoid arthritis [3], IgG4-related disease [2], adult Still's disease [2], vasculitis [1], SLE [1], drug-induced lupus [1], and Behcet's [1]. The pleural team review took place 1 day (median) after referral. 73% of diagnoses (8 patients) were achieved with local anaesthetic pleural interventions (a combination of: aspiration, drain, or percutaneous biopsy). This included 1 patient who required no pleural intervention. 1 required medical thoracoscopy, and 2 underwent thoracic surgery. Diagnoses were made by integrating all available evidence such as clinical assessment, imaging, and autoimmune serology. No diagnosis was achieved by pleural cytology or histology analysis alone. 8 (73%) were commenced on prednisolone acutely (vasculitis, SLE, drug-related lupus, 1 patient with rheumatoid arthritis, Behcet's, 2 patients with Adult Still's disease, 1 patient with IgG4-related disease). Of these 8, one patient with rheumatoid arthritis received IV methylprednisolone beforehand, one patient with IgG4-related disease was weaned off prednisolone to methotrexate, two patients with Adult Still's disease were on colchicine as well, and one patient with Behcet's was on cyclophosphamide as well. 7 (64%) were managed as outpatients; 4 required admission. The median time from pleural review to diagnosis was 53 days.

Conclusions: Diagnosis can be challenging in patients presenting with pleural disease as the first manifestation of a CTD. We recommend a multidisciplinary approach in management.

Keywords: Pleural effusion, Pleura, Thoracoscopy, Connective tissue disease
Background
A new pleural effusion may be caused by a wide range of conditions. The British Thoracic Society produced guidelines in 2010 recommending a systematic approach to achieve a diagnosis, aiming to streamline investigations and interventions [1]. Since then, the evidence base for managing malignant and infective effusions has developed through a series of clinical trials. In comparison, research on benign non-infective pleural effusions has been more limited [2]. A number of these are caused by connective tissue diseases (CTD).

Pleural effusions from CTD are caused by increased capillary permeability, as extravascular fluid moves from the lung's interstitium, across the mesothelium into the pleural space [3]. This may be due to a number of reasons [4], such as a pleural infiltrative process. In addition, circulating immune complexes that localise to the pleura, can activate the complement system causing endothelial injury. Enzyme and free radical release from white blood cells also accentuate the inflammatory process.

CTD-related pleural effusions are rare and challenging to diagnose. The most common CTDs to affect the pleura are rheumatoid arthritis and systemic lupus erythematosus (SLE) [1]. A prospective observational cohort study over 7 years at a specialist pleural unit identified 356 nonmalignant pleural effusions. 9.8% of these were given a diagnosis of inflammatory pleuritis, and 7.6% attributed to other diagnoses (including chylothorax, rheumatic causes, trauma, and drug-induced causes) [5].

The same unit described the value of a pleural specialist team to improve the efficacy and efficiency of managing patients with pleural disease [6]. In most pleural teams, the medical specialties involved are commonly: respiratory, oncology and palliative care. However, the pleural team in our centre works closely with the lung inflammation service, with expertise in rheumatology, interstitial lung disease and respiratory failure. This study aims to review the multidisciplinary approach to CTD-related pleural effusions at a tertiary centre. To our knowledge, there is no published evidence describing a multidisciplinary approach to CTD-related pleural effusions.

Methods
Study design
This study is a retrospective evaluation of cases. We reviewed electronic hospital records, imaging, blood tests, pleural fluid analysis and pleural biopsy analysis. Data were collected relating to CTD diagnosis, pleural and surgical interventions, and CTD specific systemic therapy.

As a retrospective service evaluation, written patient informed consent and regional ethics approval was not required.

Table 1 Patient demographics

| Characteristic                  | n (%) |
|--------------------------------|-------|
| Gender (n = 11)                |       |
| Male                           | 8 (73) |
| Female                         | 3 (27) |
| Age range                      | 23–77  |
| Median age                     | 50     |
| CTD diagnosis                  |       |
| Rheumatoid arthritis           | 3 (27) |
| IgG4-related disease           | 2 (18) |
| Adult Still's disease          | 2 (18) |
| Vasculitis                     | 1 (9)  |
| SLE                            | 1 (9)  |
| Drug-induced lupus             | 1 (9)  |
| Behcet’s                       | 1 (9)  |

Table 2 Pleural/surgical interventions

| Pleural intervention                      | n (%) |
|-------------------------------------------|-------|
| None                                       | 1 (9) |
| Pleural aspiration only                    | 3 (27) |
| Chest drain only                           | 2 (18) |
| Pleural aspiration and chest drain         | 1 (9)  |
| Pleural aspiration and biopsy              | 1 (9)  |
| Pleural aspiration and biopsy, drain and VATS | 1 (9) |
| Pleural aspiration and medical thoracoscopy| 1 (9) |
| VATS, thoracotomy, pericardiectomy         | 1 (9) |
### Table 3: Key clinical information of patients

| Connective tissue disease diagnosis | Presenting symptoms / Autoimmune serology | Pleural fluid glucose (mmol/L) | Pleural fluid LDH (IU/L) | Pleural fluid protein (g/L) | Pleural micro appearance | Pleural fluid cytology | Histology | CT chest findings | Outcome |
|------------------------------------|------------------------------------------|-------------------------------|--------------------------|----------------------------|--------------------------|------------------------|-----------|-----------------|---------|
| Rheumatoid arthritis               | Pleuritic chest pain, dyspnoea, polyarthralgia, fatigue anti-CCP + ve | Clinical assessment autoimmune serology | 3.4 | 794 | 55 | Fluid MCS/AFB neg/ Biopsy AFB neg | Turbid yellow fluid | 2/3/16 | Neutrophils, lymphocytes, macrophages, prominent eosinophils. Few reactive mesothelial cells. 23/3/16 Mixed lymphoid cell population; plasma cells and eosinophils. Occasional mesothelial cells. | Bilateral hilar lymphadenopathy. Left-sided pleural effusion and bibasal groundglass change with intralobular septal thickening demonstrated. | Resolution of pleural effusions on CXR by week 7 on weaning prednisolone (after pulsed methylprednisolone) |
| Rheumatoid arthritis               | Fever, cough, fatigue, pleuritic chest pain, dyspnoea, anti-CCP and RhF + ve | Previous CTD diagnosis, clinical assessment autoimmune serology | None | None | None | n/a | n/a | None | None | Pericardial hyperaeration, either in keeping with thickening and low-grade enhancement or a complex pericardial effusion. Shallow left pleural effusion. | Pleural effusion stable 1 year after discharge from pleural clinic (during which 5 mg prednisolone daily started for joint pains) |
| IgG4-related disease               | Dyspnoea, cough, oedema, IgG4 2.71 (0.23–1.11 g/L) IgG1 11.3 (4.8–9.5 g/L) | Pericardiectomy histology, autoimmune serology | None | None | None | Fluid MCS/AFB neg/ Biopsy AFB/ MCS neg | Bloodstained fluid | A few benign mesothelial cells (Pleural biopsy: mildly inflamed pleural tissue. Single non-necrotising granuloma.) | Pericardial biopsy: dense keloid-like fibrosis. Foci of chronic inflammation and in these IgG4 plasma cells comprise a high population of IgG+ plasma cells. | Right pleural effusion and ascites. Cervical and mediastinal lymphadenopathy. Pericardial calcification and thickening suggest previous pericardial effusion/pericarditis. | Pleural effusion improved over 2 months (prednisolone started then weaned off onto methotrexate) |
| IgG4-related disease               | Dyspnoea, dizziness, IgG4 1.53 (0.23–1.11 g/L) | Pericardiectomy histology, clinical assessment | None | 27 | 6 | Fluid Scanty growth Staphylococcus aureus, AFB | Slightly cloudy yellow fluid | Mesothelial cells and mixed inflammatory cells | Pericardial biopsy: Diffuse moderate to severe fibrosis associated with focal calcification and mild small bilateral pleural effusions. No pericardial effusion although some pericardial calcification is | Left pleural effusion resolved and small right pleural effusion 1 year after |
### Table 3: Key clinical information of patients (Continued)

| Connective tissue disease diagnosis | Presenting symptoms / Autoimmune serology | Evidence for diagnosis* | Pleural fluid glucose (mmol/L) | Pleural fluid LDH (IU/L) | Pleural fluid protein (g/L) | Pleural micro appearance | Pleural fluid cytology | Pleural fluid protein (g/L) | Histology | CT chest findings | Outcome |
|-----------------------------------|-------------------------------------------|------------------------|-------------------------------|-------------------------|---------------------------|--------------------------|----------------------|--------------------------|-----------|-------------------|---------|
| **Adult Still’s disease**         | Fever, cough, dyspnoea, chest pain, myalgia, sore throat, rash | Clinical assessment, raised ferritin | 10.3 | 894 | 33 | Fluid MCS/AFB neg | Straw coloured fluid | Acute inflammatory cells. A few reactive mesothelial cells, histiocytes and lymphocytes. | None | Small bilateral pleural effusions with bilateral collapse/consolidation. Moderate pericardial effusion. | Pleural effusions resolved after 1 month (weaning prednisolone and colchicine) |
| **Adult Still’s disease**         | Pleuritic chest pain, dyspnoea, fever, sore throat, arthralgia | Clinical assessment | None | None | 34 | Fluid MCS/AFB neg | Cloudy yellow fluid | Numerous neutrophils (95%) with occasional macrophages and mesothelial cells. | None | Small bilateral pleural effusions and a trace of pericardial fluid. | Pleural effusions resolved after 2 months (weaning prednisolone and colchicine) |
| **Vasculitis**                    | Dyspnoea, weight loss, appetite loss P-ANCA, Anti-MPO 222 (0-10 U/ml) | Clinical assessment, autoimmune serology, CT showing adrenal infarcts | 69 | 279 | 48 | Fluid MCS/AFB neg | Bloodstained fluid | Mixed lymphoid cell population along with neutrophil polymorphs, histiocytes and very occasional mesothelial cell. | None | Bilateral calcified pleural plaques. Right pleural thickening and effusion. Emphysema. Multiple solid subpleural and perifissural bilateral nodules | Pleural effusion resolved after 5 months (4 month course of weaning prednisolone) |
| **SLE**                           | Pleuritic chest pain, dyspnoea Anti ds-DNA 415 (0-10 IU/ml), anti-Smith +ve | Previous CTD diagnosis, clinical assessment | 5.2 | 304 | 59 | Fluid MCS/AFB neg | Cloudy light brown fluid | Mesothelial cells, macrophages, neutrophils and lymphocytes. | None | None | Pleural effusion resolved after 7 months (prednisolone weaned to maintenance) |
| **Drug-induced lupus (cabamazepine)** | Dyspnoea, rash, ulceration of hands and feet ANA +ve, ENA RNP + ve, ENA SSA (Ro) + ve, ENA Sm + ve ANCA neg | Clinical assessment, autoimmune serology | 6.5 | 228 | 47 | Fluid MCS/AFB neg | Turbid orange fluid | Reactive mesothelial cells, polymorphs, lymphocytes and histiocytes 5/12/12 Numerous mesothelial cells, macrophages | 16/11/12 pleural biopsy: Single focus of large cells at the edge of one fragment, most likely reactive mesothelial cells. Nuclei are pleomorphic, irregular nuclear membranes and nuclear chromatin clearing. 13/11/13 pleural biopsy: Pleura markedly oedematous; granulation | Left pleural effusion with minimal nodularity and mild volume loss in the left hemithorax. Shallow pericardial effusion. Widespread mild lymphadenopathy. | Pleural effusion resolved after 9 months (prednisolone weaned to maintenance) |
| Connective tissue disease diagnosis | Presenting symptoms / Autoimmune serology | Evidence for diagnosis* | Pleural fluid glucose (mmol/L) | Pleural fluid LDH (IU/L) | Pleural fluid protein (g/L) | Pleural micro appearance | Pleural fluid cytology | Histology | CT chest findings | Outcome |
|-----------------------------------|------------------------------------------|------------------------|-------------------------------|--------------------------|--------------------------|--------------------------|------------------------|-----------|------------------|---------|
| Behcet’s chest tightness           | Clinical assessment                       | 48                     | 380                           | 44                       | Fluid MCS/AFB neg         | Turbid bloodstained fluid | Numerous lymphocytes, histiocytes and blood. | none      | Large right main pulmonary artery thrombus. Multiple left sided pulmonary emboli. Bilateral pleural effusions with consolidation/atelectasis. 2 small round pulmonary foci and a band of consolidation in the right upper lobe. Wedge-shaped consolidation in the middle and right lower lobes. | Pleural effusions resolved after 1 year (cyclophosphamide and weaning prednisolone) |

*These were the key factors used by the multidisciplinary team in securing a diagnosis.
and to summarise the clinical characteristics of the subjects.

Results
Eleven patients (ages 23–77) were identified with CTD related pleural disease (Table 1). They were seen by the lung inflammation service, who performed an expert clinical assessment and targeted investigations, usually after review by the pleural team. 9 (82%) patients were given a new CTD diagnosis, with pleural disease as the first manifestation. The range of conditions were: rheumatoid arthritis [3], IgG4-related disease [2], adult Still’s disease [2], vasculitis [1], SLE [1], drug (carbamazepine)-induced lupus [1], and Behcet’s [1].

The pleural team review took place 1 day (median) after referral. 73% of diagnoses (8 patients) were achieved with local anaesthetic pleural interventions (a combination of: aspiration, drain, or percutaneous biopsy). This included 1 patient who required no pleural intervention. 1 required medical thoracoscopy, and 2 underwent thoracic surgery (Table 2). The patient who underwent a medical thoracoscopy (for pleural thickening) after an aspiration, had a final diagnosis of a rheumatoid arthritis associated pleural effusion. One patient who underwent thoracic surgery was referred directly to the surgical team, subsequently requiring a pericardiectomy for a diagnosis of IgG4-related disease. Another patient underwent VATS to rule out a pleural malignancy, before commencing treatment for a pleural effusion related to drug-induced lupus.

Table 3 illustrates how diagnoses were made by integrating and analysing all available evidence, to include clinical assessment, imaging, and autoimmune serology. No diagnosis was achieved by pleural cytology or histology analysis alone. The pleural fluid pH was not measured for these patients (although it is available at our centre), as pleural infection was low on the list of differentials.

Eight (73%) were commenced on prednisolone acutely (vasculitis, SLE, drug-related lupus, 1 patient with rheumatoid arthritis, Behcet’s, 2 patients with Adult Still’s disease, 1 patient with IgG4-related disease). Of these 8, one patient with rheumatoid arthritis received IV methylprednisolone beforehand, one patient with IgG4-related disease was weaned off prednisolone to methotrexate, two patients with Adult Still’s disease were on colchicine as well, and one patient with Behcet’s was on cyclophosphamide as well. 7 (64%) were managed as outpatients; 4 required admission. The median time from pleural review to diagnosis was 53 days.

Discussion
In the work up for interstitial lung disease (ILD), assessment by a rheumatologist is recommended in suspected CTD [9]. The input of a rheumatologist is invaluable in providing an expert clinical review, then directing and interpreting autoimmune testing. Our centre has found this to be the case – in managing CTD-related pleural effusions. The lung inflammation service was set up to assist the critical critical care team in managing severe respiratory failure; they now work closely with the pleural service as well. To our knowledge, this is the first published evaluation of a collaborative approach for inflammatory pleural disease. Case reports of CTD-related serositis do not describe a similarly coordinated approach [10–12]. Our results suggest that the value of pleural fluid and tissue analysis is to exclude common conditions such as malignancy and infection, while a multidisciplinary approach integrating all available diagnostic information is needed for complex cases such as CTD related pleuritis.

In this service evaluation, the multidisciplinary approach to CTD-related pleural effusions has demonstrated efficiency in achieving a diagnosis in a median of 53 days from the first review by the pleural team. Pleural procedures were streamlined, with 73% of diagnoses being achieved by local anaesthetic interventions. 64% of cases were managed in the outpatient setting. Published data describe the outcomes of pleural service outcomes as a whole [13, 14]. This is the first study to focus on the management of CTD-related pleural effusions.

The study was limited by the small number of cases, due to the rarity of CTD-related pleural effusions. A multi-centre collaboration to establish a larger database would facilitate advancement in best managing this complex patient cohort.

Conclusions
Diagnosis can be challenging in patients presenting with pleural disease as the first manifestation of a CTD. We recommend a multidisciplinary approach in management.

Abbreviations
CTD: connective disease disease; ILD: interstitial lung disease; SLE: systemic lupus erythematosus; VATS: video-assisted thoracoscopic surgery

Acknowledgements
We would like to thank all the patients involved in this study. We are also indebted to the pleural team of doctors and nurses for facilitating each patient’s journey in clinic.

Authors’ contributions
HI contributed to study design, data collection, statistical analysis, data interpretation, clinical care and wrote the first draft of the manuscript. PS contributed to study design, data collection, statistical analysis, data interpretation, clinical care and manuscript drafting. LA participated in data collection and manuscript drafting. SA, BL and AW contributed to data interpretation, clinical care and manuscript drafting. HI conceived the study and contributed to clinical care, statistical analysis, data interpretation and manuscript drafting. All authors read and approved the final manuscript.

Authors’ information
HI is a respiratory registrar, and clinical research fellow in pleural disease. PS is a respiratory registrar, post-graduate MD student and trial coordinator of the OPTIMUM trial. EAM is a medical student.
SA is a rheumatology consultant.
BL is a respiratory consultant with specialist interests in interstitial lung disease and respiratory failure.
AW is a respiratory consultant with specialist interests in pleural disease and interstitial lung disease.
LA is a respiratory consultant with specialist interest in pleural disease, Senior Honorary Lecturer at KCL, and the Chief Investigator for OPTIMUM trial. LA has secured funding from Becton and Dikinson Ltd. for the OPTIMUM trial.

Funding
Open access for this article was funded by King’s College London.

Availability of data and materials
Due to our local governance policy, we do not have permission to make the data sets on which the conclusions of the paper rely publicly available. A truncated data set (removing all potentially identifying features) may be made available on an individual request basis.

Ethics approval and consent to participate
As a retrospective service evaluation, written patient informed consent and regional ethics approval was not required.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 4 July 2018 Accepted: 14 August 2019
Published online: 27 August 2019

References
1. Hooper C, Lee YCG, et al. British Thoracic Society pleural disease guideline 2010. Thorax. 2010;65(Suppl 2):ii4–i17.
2. Bintcliffe OJ, Lee YCG, et al. The management of benign non-infective pleural effusions. Eur Respir Rev. 2016;25:303–16.
3. Ferreiro L, Álvarez-Dobaño JM, Valdés L. Systemic diseases and the pleura. Arch Bronconeumol. 2011;47(7):361–70.
4. Joseph J, Sahn SA. Connective tissue diseases and the pleura. Chest, 1993; 104:262–70.
5. Walker SP, Morley AJ, et al. Nonmalignant Pleural Effusions. Chest. 2017; 151(5):1099–105.
6. Bhataragor R, Makkeli N. Developing a ‘pleural team’ to run a reactive pleural service. Clin Med. 2013;13(5):452–6.
7. Rahman NM, Ali NJ, et al. British Thoracic Society pleural disease guideline 2010. Thorax. 2010;65(Suppl 2):i64–60.
8. Havelock T, Teoh R, et al. British Thoracic Society pleural disease guideline 2010. Thorax. 2010;65(Suppl 2):i61–76.
9. Patron JD, Mahar A, et al. The interstitial lung disease multidisciplinary meeting: a position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia. Respirology. 2017 Oct; 22(7):1459–72.
10. Akagi T, Mukai T, Kodama S, et al. POEMS syndrome in a patient with rheumatoid arthritis. Case Rep. 2017;2017:bcr-2017-220875.
11. Szeto MCH, Disney B, Perkins P, et al. Ascites and other incidental findings revealing undiagnosed systemic rheumatoid arthritis. Case Rep. 2015;2015: bcr2014207142.
12. Malone C, McCarthy G. Polymyalgia Rheumatica as an unusual cause of pleural and pericardial effusion. J Clin Rheumatol. 2005;11:59–60.
13. Fawzi A, Maddekar N, Khan S, et al. M20 Pleural service in a large university teaching hospital – 1 year retrospective review. Thorax. 2016;71:A268.
14. Brookesby C, Wells A, Deegan P, et al. P13 the rationale for setting up a dedicated pleural procedure list: benefits for patients and trusts. Thorax. 2016;71:A90.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.